WHAT THIS PAPER ADDS This study examines the outcomes following off-licence use of rFVIIa to control critical bleeding in patients during abdominal aortic aneurysm (AAA) repair. Patients who stopped/attenuated bleeding after rFVIIa use had a lower mortality than those with continuous bleeding. However, predictive mortality models did not show improved survival after rFVIIa administration. Further studies are needed to more thoroughly explore the precise role of rFVIIa in these patients with high risk of mortality as clinicians are likely to continue using rFVIIa when conventional methods have failed and patient is at risk of exsanguination.
INTRODUCTION
In recent decades, advances have been made in the management of patients with Abdominal Aortic Aneurysms (AAA), including improved diagnostic techniques, introduction of endovascular aneurysm repair procedures (EVAR), improved post-operative intensive care and an increase in the number of specialist vascular surgeons. 1, 2 Despite these advances, the mortality associated with AAA ranges from 3%e54% for elective repair of non-ruptured AAAs (nr-AAA) to 30%e70% in ruptured AAA (r-AAA). 3e8 Surgical repair (either open procedures or EVAR) is currently the only active treatment option available to patients with r-AAA. However, due to uncontrolled haemorrhage and coagulopathy, many patients do not survive surgical intervention. 9 Mechanisms postulated to be associated with coagulopathy in r-AAA patients include consumption of platelets and clotting factors within aneurysmal thrombi, dilution of clotting factors and platelets through blood loss, fluid therapy and blood transfusions and the adverse effects of acidosis and hypothermia on platelet function. 10, 11 Consequently, there is growing interest in adjunctive therapies for treating critical bleeding in AAA patients. Haemostatic agents such as recombinant activated Factor VII (rFVIIa, NovoSeven Ò , Novo Nordisk A/S, Bagsvaerd, Denmark) have been widely used with an aim to control haemorrhage and restore haemostasis in settings such as trauma, 12, 13 cardiac surgery, 14, 15 liver surgery, 16, 17 and obstetrics. 18, 19 While rFVIIa is licensed for use in the treatment of Haemophilia A and B with inhibitors, congenital Factor VII deficiency and Glanzmann's thrombasthenia, the number of patients receiving rFVIIa off-licence now exceeds those receiving on-licence treatment. 20 In AAA, data on the use of rFVIIa is scarce; however, case reports and series suggest that effective administration of rFVIIa may be associated with improved patient outcomes. 9, 21, 22 In this manuscript, we sought to describe the use of rFVIIa in patients diagnosed with AAA (ruptured and nonruptured) and their outcomes, using data from the Australian and New Zealand Haemostasis Registry (ANZHR). In addition, we compared the expected versus observed mortality in ANZHR AAA patients in different severity strata using published mortality prediction models.
METHODS

The Australian and New Zealand Haemostasis Registry (ANZHR)
The ANZHR is a register of non-haemophiliac patients treated with off-licence rFVIIa for episodes of critical bleeding in Australia and New Zealand. Details of this registry have been previously published elsewhere. 23 The ANZHR was established in the Department of Epidemiology and Preventive Medicine (DEPM) at Monash University and funded through an unrestricted educational grant from Novo Nordisk Pharmaceuticals Pty Ltd. The registry was established in 2005 and included retrospective data collection resulting in cases spanning a ten-year period (2000e2009). The 96 participating hospitals included all major teaching hospitals throughout Australia and New Zealand and participation required hospitals to commit to registration of every off-licence use of rFVIIa at their institution.
Patients in the ANZHR were identified by local investigators through blood bank or pharmacy records of rFVIIa administration. Trained data collectors extracted data from medical records using a standardised case report form that captured information related to: patient demographics (e.g. age, gender); details of rFVIIa use (dose volume, body temperature and blood pH); blood components transfused before and after rFVIIa use (red blood cells (RBCs), fresh frozen plasma (FFP), cryoprecipitate and platelets); use of anticoagulant/antithrombotic medications prior to rFVIIa use; clinician-assessed effect of rFVIIa on bleeding (stopped, attenuated or unchanged e this was a subjective assessment based on clinical judgement); thromboembolic (TE) adverse events, and mortality (24-h and 28-day). Patients who either stopped or attenuated bleeding after rFVIIa administration were categorised as responders whereas patients with unchanged bleeding conditions were classified as non-responders.
All data entries were verified and validated by registry staff prior to inclusion on the registry. Data collected as part of the ANZHR were subject to a rigorous quality control and auditing process. 24 Those patients receiving rFVIIa for treatment of bleeding associated with AAA were identified from text descriptions of the case. Data collectors at each site were contacted to provide additional details (supplementary data) on AAA cases to allow calculation of the Hardman Index 25 and the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM), 26 which have been used previously as mortality prediction tools in AAA patient populations. Additional information was also requested including aneurysm status (ruptured or non-ruptured), urgency of surgery, type of surgery (open or EVAR) and location of aneurysm.
The registry received ethics approvals from the Human Research Ethics Committees of Monash University and all participating hospitals to collect de-identified information without patient consent.
Statistical analysis
All statistical analyses were performed using Stata version 11.2 (StataCorp, College Station, Texas, USA). We compared characteristics and outcomes between ANZHR responders and non-responders to rFVIIa. This analysis was performed separately for patients presented with ruptured and nonruptured AAAs. Categorical variables were compared using Fisher's Exact Chi-Squared tests and continuous variables using ManneWhitney (ranksum) tests. Logistic regression analyses were carried out to identify predictors associated with mortality. In addition, mortality risk in r-AAA patients in the ANZHR was scored using the Hardman Index 25 and a POSSUM model specifically for r-AAA as described by Prytherch et al. 26 (R-POSSUM). The mortality risk in patients with nr-AAA was scored according to the V-POSSUM model as outlined by Tambyraja et al. 27 Table 1 outlines the variables and equations of POSSUM models plus the variables used for Hardman Index calculations. Each variable included in the Hardman Index scores one point each and patients were scored from 0 (lease severe) to 5 (most severe). A P-value less than 0.05 was regarded as statistically significant.
RESULTS
Of the 3440 patients in the ANZHR, 106 (3%) had AAA as the primary context of bleeding. Of these, additional (supplementary) data were available for 77 (73%). Characteristics of patients with and without supplementary information showed no significant difference in demographics, rFVIIa dose size, bleeding response to rFVIIa or mortality ( Table 2 ). The analysis was therefore restricted to patients with 
supplementary data who were treated in 27 different hospitals across Australia and New Zealand (Fig. 1 ).
Approximately 84% (n ¼ 65) of the AAA patients were male, and their median (IQR) age was 73 (69e79) years ( Table 2 ). Seventy-one patients (92%) were admitted to the intensive care unit (ICU) following surgery: the 6 patients who did not get admitted to the ICU were deceased within 24 h. Over 80% (n ¼ 63) of AAA patients received only a single dose of rFVIIa and the median (IQR) rFVIIa dose was 82 (60e96)mg/kg. Approximately 46% (28/61) of patients were severely acidotic (serum pH < 7.2) and 34% (20/58) were hypothermic (core temperature <35 C) at the time of rFVIIa use. Bleeding response to rFVIIa was known for 70 patients and 35 (50%) of them either stopped or attenuated bleeding after rFVIIa administration (positive responders). Nine patients had records of thromboembolic (TE) adverse events (please see below for details) and by day 28 following rFVIIa use, 47 (61%) patients were deceased ( Table 2) .
The majority of patients (n ¼ 56, 73%) had ruptured aneurysms (r-AAA) at the time of hospital admission. About 75% (n ¼ 58) these surgeries were emergency procedures with over 80% (n ¼ 57) having infra-renal aneurysms. Fiftythree percent (10/19) of the non-ruptured (nr-AAA) and 49% (25/51) of r-AAA patients responded positively to rFVIIa. Approximately 93% (n ¼ 71) of patients underwent open surgical repair while the remaining 7% (n ¼ 5) had endovascular repair (EVAR). All 5 patients with EVAR (2 r-AAA and 3 nr-AAA) had returned to the ICU following surgery. Two of these EVAR patients (1 r-AAA and 1 nr-AAA patient) responded positively to rFVIIa resulting in stopped/attenuated bleeding. The 3 EVAR patients who did not respond to rFVIIa died within 24 h after surgery. The r-AAA patient with EVAR and demonstrated a positive response to rFVIIa was also dead by day 28. Overall, 28-day mortality among these patients who underwent EVAR was 80% (4/5). Table 3 reports the comparison of aneurysm details, patient characteristics and outcomes between responders and non-responders, stratified by aneurysm state. No statistically significant differences were found between responders and non-responders in terms of patient aneurysm details for either ruptured or non-ruptured AAA. The single patient characteristic to demonstrate a statistically significant difference between responders and nonresponders related to acidosis: significantly more nonresponders in both nr-AAA and r-AAA patient groups were acidotic (none vs. 71% (5/9) in nr-AAA group and 32% (7/25) vs. 75% (15/26) in r-AAA group). In terms of patient outcomes, approximately 24% (6/25) of responders in the r-AAA group but none of the non-responders experienced TE adverse events (P ¼ 0.01). The 24-h mortality was significantly higher in non-responders in both ruptured and non-ruptured AAA patient groups (Table 3) . Additionally, the 28-day mortality in r-AAA non-responders was 92% (24/26), which was significantly higher than the responders (40% (10/25), P < 0.01). The 28-day mortality rate in nr-AAA non-responders was also higher than nr-AAA responders (67% (6/9) vs. 30% (3/10)) although the difference was not statistically significant.
Furthermore, we examined the association between 28day mortality in ruptured AAA patients and a range of factors including infra-renal aneurysm, gender, age, prior medication use, acidosis, hypothermia, TE adverse events and non-response to rFVIIa. In univariate analyses, only non-response to rFVIIa was found to be significantly associated with 28-day mortality in r-AAA patients (OR ¼ 18 [95% CI: 3e94] P < 0.001). Logistic regression analyses were not performed with nr-AAA group due to the small number of patients. 3 7(n ¼ 2 nr-AAA; n ¼ 5 AAA), 4 1 (n ¼ 1 AAA), 5 9 (n ¼ 1 nr-AAA; n ¼ 8 AAA), 6 14 (n ¼ 4 nr-AAA; n ¼ 10 AAA), 7 12 (n ¼ 3 nr-AAA; n ¼ 9 AAA) patients. P-values compare responders with non-responders. For differences in medians (continuous variables) P-values derived using ManneWhitney (ranksum) tests and using Fisher's exact Chi-Squared tests for categorical variables.
Thromboembolic (TE) adverse events in detail
A total of 11 TE adverse events were reported among 9 AAA patients (12%) and the details are as presented in Table 4 . Six of the 9 patients with TE adverse events had ruptured aneurysms. Interestingly, all these 6 r-AAA patients had responded positively to rFVIIa either stopping or attenuating bleeding. Of the 3 nr-AAA patients with TE adverse events, one had responded positively to rFVIIa, one had not responded to rFVIIa and response was recorded (unknown) for one patient. Two of these patients with TE events were on aspirin and another 2 were using Warfarin prior to surgery. While all 9 patients survived the first 24 h, 4 patients were deceased by day 28 (3 r-AAA patients and 1 nr-AAA patient with unknown bleeding response).
POSSUM scores and Hardman Index in HR AAA patients
Mortality in ANZHR AAA patients was further compared to predicted mortality, calculated using the Hardman Index ( Fig. 2 ) and POSSUM model: R-POSSUM for patients with r-AAA and V-POSSUM for nr-AAA (Table 5 ). Although there were differences between observed and expected deaths in some categories, there was no statistically significant difference between overall observed and predicted mortality with any model.
DISCUSSION
Our aim was to investigate the use of rFVIIa in patients presenting with AAA and to describe their outcomes using data from the Haemostasis Registry. To our knowledge, this is the largest study of the off-label use of rFVIIa in this patient group. In a univariate logistic regression analysis, we observed a statistically significant association between positive bleeding response to rFVIIa and reduced mortality in r-AAA patients. Mortality prediction models however did not provide evidence to support this observation. Surgery for AAA, especially in those with ruptured aneurysms, carries a great risk of haemorrhage largely due to coagulopathy, which is known to be a major cause of intra-operative mortality. 28 Various mechanisms are implicated in coagulopathy: tissue injury can lead to platelet and clotting factor consumption (consumption coagulopathy), prolonged operation time, global hypoperfusion and intraoperative replacement of large volumes of non-warmed fluids can contribute to both hypothermia and dilutional coagulopathy. 9 In addition, hypoperfusion due to crossclamping and subsequent reperfusion after unclamping is thought to induce fibrinolysis and acidosis. In turn, both hypothermia and acidosis can contribute to clotting factor dysfunction, resulting in refractory coagulopathy. 9 Modern management of patients undergoing AAA repair with perioperative haemorrhage includes cell salvage mechanisms, rapid administration of large amounts of red blood cells (RBCs), platelets and plasma to prevent and treat coagulopathy. 9, 11 Additionally, procedures to minimise hypothermia (e.g. use of warm fluid infusion, forced air warming and warm saline in surgical field) and correction of acidosis at an early stage, may be used to prevent coagulopathy. 10 However, in those situations when bleeding is uncontrollable and all conventional measures are ineffective, rFVIIa has been used as an adjunctive therapy.
Approximately 50% of the Haemostasis Registry AAA patients did not demonstrate any change in bleeding condition after rFVIIa use, with the majority of these 'nonresponders' found to be acidotic at the time of rFVIIa use. The precise impact of acidosis and hypothermia on rFVIIa activity is an ongoing debate, with current evidence limited to in vitro studies that report inconsistent results. 29, 30 In the present study, a significantly greater number of nonresponders were found to be acidotic (but not hypothermic) at the time of rFVIIa administration, in both ruptured and non-ruptured AAA cases. Yet, upon regression analysis, only response to rFVIIa was found to be significantly associated with increased survival. This observation suggests that response to rFVIIa may have influenced patient survival in Haemostasis Registry AAA patients.
A limited number of studies investigating the use of rFVIIa in AAA patients have reported improved survival in those who demonstrate a reduction in or cessation of bleeding. von Heymann et al. published a meta-analysis of case series, and demonstrated that 73% of patients treated with rFVIIa during abdominal, vascular and urological surgery achieved at least a reduction of bleeding and that the probability of survival was increased in these patients. 31 Koncar et al. recently published one of the largest case series (n ¼ 24) of vascular patients treated with rFVIIa. 9 They compared the use of rFVIIa for intractable bleeding in r-AAA and thoracoabdominal aortic aneurysm (t-AAA) patients to a historical control group and found a significant reduction both in mortality and transfusion requirements. While the patients with rFVIIa use (cases) were recruited from July 2003 to January 2008, the control patients were from January 1995 to July 2003, before rFVIIa was made locally available. 9 Advances in medical and surgical treatment between 1995 and 2008 are likely to have biased results in this study towards a reduced mortality in the latter period that may confound any improvements due to use of rFVIIa.
Since the patient population in this study was recruited from several hospitals across Australia and New Zealand, the treatment regimens in different hospitals would have resulted in different management of patients causing potentially different outcomes. This is a source of variation and a limitation of this observational study. Additionally, subjective assessment of bleeding response to rFVIIa might have caused some variation in bleeding outcome definition, which is another limitation of this study. However, current alternative methods for assessing bleeding response are also similarly problematic. While coagulation parameters such as PT and APTT may be used as indirect indicators of response, these measures do not reflect real-time efficacy of rFVIIa in critical bleeding contexts. Also, while the demand for blood components offers a potentially useful tool for assessing response, reliable collection of these and similar data is also difficult. As part of quality control procedures, the registry provided training in data abstraction to ensure standardised assessment of parameters including bleeding response and undertook regular data auditing procedures. 24 Therefore, we believe that clinical judgement was a reasonable tool for assessing bleeding response in this context.
To date, there have been no clinical trials investigating the use of rFVIIa for the treatment of bleeding in patients with AAA. Without an appropriate comparator or control group, and with the mortality prediction tools showing no overall benefit in mortality rate, it is difficult to rule out the possibility that Haemostasis Registry patients who survived, would have survived regardless. Furthermore, not all variables that may impact outcomes in patients with AAA (such as if the AAA was symptomatic or mycotic etc.) were included in the original data collection for the ANZHR. Although this study is one of the largest of its type, the sample size in the analysis remains small. Nonetheless, the strong association between non-response to rFVIIa and mortality observed in the Haemostasis Registry AAA patients is difficult to over-look. Therefore, further studies are needed to more thoroughly explore the precise role of rFVIIa in these very high mortality-risk patients. In the meantime, clinicians are likely to continue using rFVIIa in cases when conventional therapeutic options have failed and the patient is at risk of exsanguination.
In other studies of ruptured AAA patients, the mortality rates assessed against POSSUM risk categories are highly variable, although patient numbers per study are typically small. Bown et al. reported only 57% (4/7) mortality in patients with mortality risk above 75%, 5 while Sandford et al. reported 75% mortality (3/4) in patients with greater than 80% mortality risk. 32 Another larger series by Harris et al. reported 84% mortality in patients with mortality risk above 80%, 33 while for the same risk group Neary et al. reported 89% mortality. 34 In our study, observed mortality in r-AAA patients receiving rFVIIa who had a mortality risk >80%, was 79% (11/14) . Therefore, since overall predicted and observed mortalities were similar despite several differences at different risk strata, evidence from this analysis does not allow us to conclude that use of rFVIIa made a statistically significant contribution to improved survival.
CONCLUSION
Observations in this study suggest that Haemostasis Registry AAA patients were gravely ill and those who responded positively to rFVIIa had an improved survival rate. Despite this, predictive models of mortality did not show improved survival following rFVIIa administration. Carefully planned, randomised clinical trials in this patient population are therefore required to help identify if and when rFVIIa should be used in this patient group at high risk of exsanguination.
